{"schema_version":"secwatch.filing_event.v1","accession":"0001615219-24-000019","form_type":"8-K","ticker":"DCOY","cik":"0001615219","company_name":"Decoy Therapeutics Inc.","filed_at":"2024-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.811957+00:00","generated_at":"2026-06-05T02:41:37.289625+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Salarius Pharma gets Nasdaq extension to Sep 3 for bid price compliance; will pursue reverse split if needed","bullets":["Nasdaq granted Salarius until Sep 3, 2024 to regain $1.00 minimum bid price compliance.","Bid price must close at or above $1.00 for 10 consecutive business days by September 3.","Company notified Nasdaq it will seek a reverse stock split if necessary to meet the requirement.","Failure to regain compliance by Sep 3 could lead to delisting notice and appeal process.","September 2023 non-compliance letter gave until March 4, 2024; extension now granted."],"urls":{"canonical":"https://secwatch.observer/filing/0001615219-24-000019","json":"https://secwatch.observer/filing/0001615219-24-000019.json","markdown":"https://secwatch.observer/filing/0001615219-24-000019.md","text":"https://secwatch.observer/filing/0001615219-24-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1615219/000161521924000019/0001615219-24-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1615219/000161521924000019/flks-20240305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T02:41:37.289625+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4c57c0908a0805a9703bc5f481c1992e0806d5c6","claim":"Decoy Therapeutics Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"int the Company would have an opportunity to appeal the delisting determination to a Nasdaq Listing Qualifications Panel (the “Panel”), but there can be no assurance that the Panel would grant the Company’s request for continued listing. As a condition of the Approval imposed by Nasdaq Listing Rule 5810(c)(3)(a), the Company notified Nasdaq that it would seek to implement a reverse stock split, if necessary, to regain compliance with the Bid Price Rule. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1615219/000161521924000019/0001615219-24-000019-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}